Completed Clinical Trials

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

By April 24, 2017 No Comments



Estimated Enrollment: 53

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: AVF3442S

Study First Received: February 22, 2006

Last Updated: November 4, 2016

Estimated Primary Completion Date: June 2010


Primary Outcome Measures:

Progression Free Survival Rate at 6 Months|Response Rate|Overall Survival

Sponsors and Collaborators:

University of Texas Southwestern Medical Center|University of Chicago|Columbia University|Duke University

Website Link:

Leave a Reply

Call Now ButtonCall Now